Exenatide controlled-release - Avadel Pharmaceuticals

Drug Profile

Exenatide controlled-release - Avadel Pharmaceuticals

Alternative Names: Exenatide extended-release - Avadel; FT 228; GLP-1 XL

Latest Information Update: 04 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Flamel Technologies
  • Developer Avadel Pharmaceuticals
  • Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Diabetes mellitus

Highest Development Phases

  • Phase I Type 2 diabetes mellitus

Most Recent Events

  • 28 Mar 2017 Avadel's Exenatide controlled-release is available for licensing as of 28 Mar 2017. http://www.avadel.com
  • 03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals
  • 31 Aug 2016 Flamel Technologies completes phase Ib trial for Type 2 diabetes mellitus before August 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top